Brief: Elicera Therapeutics Drug Candidate Gets Orphan Drug Designation In U.S.
13/01/2025 10:16
Jan 13 (Reuters) - Elicera Therapeutics AB ELIC.ST :
* ELICERA THERAPEUTICS' DRUG CANDIDATE ELC-100 RECEIVES
ORPHAN
DRUG DESIGNATION IN THE U.S. FOR THE TREATMENT OF PANCREATIC
NEUROENDOCRINE TUMORS
* FINAL DATA FROM FIRST PART OF ELC-100 STUDY EXPECTED
MID-2025
Source text: ID:nWkrDZL51
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Nomination Committee Proposes Margareth Jorvid As Chair Of Elicera Board
Brief: Elicera Therapeutics Carries Out Rights Issue Of About SEK 73 Mln
Sweden's Elicera Therapeutics Q1 loss narrows, reports positive clinical progress
Brief: Elicera Therapeutics Q1 Operating Loss SEK 5.1 Mln
Brief: Elicera Therapeutics Gets Notice Of Allowance For Japanease Patent